Announced
Completed
Synopsis
CSL, a biotechnology company, completed the acquisition of Vifor Pharma, a pharmaceuticals company, for $11.7bn. “Vifor Pharma's strategy has been to focus towards continuing being a market leader in iron deficiency, nephrology and cardio-renal therapies. The offer provides an excellent strategic opportunity for Vifor Pharma to optimize future market opportunities from a position of strength and to create substantial value for all stakeholders," Jacques Theurillat, Vifor Pharma Chairman. On January 18, 2022, CSL published offer prospectus on public tender offer for all publicly held shares of Vifor Pharma.
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.